Home Report Store Regenerative Medicine Market

Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, Tissue Engineering) Application (Musculoskeletal, Cancer, Cardiovascular, Immunology, Dermatology, Ophthalmology) End User - Global Forecast to 2031

Report ID:MRHC - 1041181 Pages: 248 Sep-2024 Formats*: PDF Category: Healthcare Delivery: 2 to 4 Hours

The Regenerative Medicine Market was valued at $7.91 billion in 2023. This market is expected to reach $37.27 billion by 2031 from an estimated $9.52 billion in 2024, at a CAGR of 21.5% during the forecast period from 2024 to 2031.

Regenerative Medicine Market Size & Forecast

This market's growth is driven by factors such as increasing approvals for regenerative medicine, advancements in regenerative medicine, the rising incidence of chronic health conditions, increasing therapeutic applications of regenerative medicine, and increasing R&D funding in regenerative medicine.

Furthermore, the increasing demand for personalized medicine, the growing need for healthy organs for transplant, and the growing number of drugs in the pipeline are expected to create market growth opportunities.

Regenerative Medicine Market Growth Drivers

Increasing Approval for Regenerative Medicine

Regenerative medicine harnesses the body’s inherent healing capabilities to restore, repair, or cultivate damaged or diseased tissues. The regenerative medicine field has witnessed a surge in interest in recent years, driven by its promising applications in oncology, cardiology, neurology, and other medical domains. With the increasing application areas of regenerative medicine, regulatory bodies are approving the use of regenerative medicine for treating different diseases. Some instances of such approvals are as follows:

In December 2023, Vertex Pharmaceuticals Incorporated (U.S.) received approval from the U.S. FDA for CASGEVY, a cell-based gene therapy designed for the treatment of sickle cell disease (SCD) in patients aged 12 years and older.
In April 2023, Gamida Cell Ltd. (U.S.) received the U.S. FDA for Omisirge (omidubicel-only), an allogeneic cell therapy indicated for use in patients aged 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning. The therapy aims to reduce the time to neutrophil recovery and the incidence of infection.

Increasing Incidence of Neurodegenerative Disorders

Regenerative medicine is proving to be an effective therapy for various medical conditions, including cardiovascular diseases, ophthalmic diseases, oncology, neurological diseases, immunology & inflammation, musculoskeletal diseases, and dermatological diseases. The growing incidence of these target diseases is a key driver for market growth.

Neurodegenerative disorders, characterized by neuron loss, represent a significant portion of these conditions. Major neurodegenerative disorders include Alzheimer's disease and other memory disorders, Parkinson's disease, Ataxia, and Huntington's disease.

According to the Alzheimer's Association (U.S.), the number of people living with Alzheimer's disease is expected to reach 13 million by 2050 from 6.9 million in 2024 in the U.S. The care cost for people living with dementia is estimated to reach about $1 trillion in 2050 in the U.S. To reduce the high prevalence and cost associated with the disease, healthcare providers are focusing on the use of stem cell therapy for therapeutic purposes. For instance, in April 2024, Regeneration Biomedical (U.S.) started the human clinical trial for RB-ADSC, an autologous stem cell treatment for people living with mild-to-moderate Alzheimer’s disease.

Regenerative Medicine Market Opportunity

Growing Need for Healthy Organs for Transplant

The global demand for organ transplantation is steadily rising due to various factors, such as increasing cases of chronic diseases leading to organ damage, genetic disorders, accidental injuries, and physical trauma to organs. According to the U.S. Health Resources & Services Administration, as of March 2024, there were 106,441 patients in the U.S. awaiting organ donation.

Regenerative medicine modalities, such as stem cell therapy and tissue engineering, play a crucial role in repairing or regenerating damaged organs, thereby reducing reliance on donor organs and enhancing transplant outcomes. While the development of organs in vitro is still in its nascent stage, regenerative medicine presents an opportunity for organ development using a patient's cells, thereby reducing the likelihood of rejection and the need for donor organs.

Regenerative Medicine Market Trends

Utilization of 3D Bioprinting in Regenerative Medicine

3D bioprinting is a cutting-edge technique in regenerative medicine, utilizing biomaterials and cells, as opposed to traditional polymers and metals, to fabricate functional 3D tissues. This technology has gained prominence for creating highly specialized tissue models, complementing conventional tissue engineering methods.

In tissue engineering, 3D bioprinting plays a crucial role in assembling living cells, biochemicals, or biomaterials into functional tissue-like structures. 3D bioprinting enables the integration of engineered tissue with natural tissue, facilitating the restoration of organ and tissue function.

Due to its advantages, 3D bioprinting is gradually replacing traditional technologies. Unlike conventional methods, 3D bioprinting ensures accurate scaffold creation and proper cell line interaction. Moreover, it enables the fabrication of tissue components from patients' stem cells, thereby reducing the risk of rejection and graft-versus-host reactions, leading to increased adoption of this innovative approach.

Induced Pluripotent Stem Cells

Induced Pluripotent Stem (iPS) cells are taken from a patient and reprogrammed so that they can differentiate into any type of cell in the body. By maintaining the patient's genetic code, iPS cells play a crucial role in disease modeling and regenerative medicine.

Induced Pluripotent Stem Cells (iPSC) are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. For example, iPSCs can be manipulated into becoming beta islet cells to treat diabetes, blood cells to create new cancer-free blood for leukemia patients and neurons to treat neurological disorders. As research on induced pluripotent stem cells advances, iPSCs are expected to emerge as a promising solution in regenerative medicine.

Regenerative Medicine Market Analysis: Key Findings

By Product: In 2024, the Cell Therapies Segment to Dominate the Regenerative Medicine Market

Based on product, the regenerative medicine market is segmented into gene therapy, cell therapy, and tissue engineering products. In 2024, the cell therapy segment is expected to account for the largest share of 51.2% of the regenerative medicine market. This segment is projected to reach $23,234.7 million by 2031 from an estimated $4,870.8 million in 2024, at a CAGR of 25.0% during the forecast period. This segment’s large market share is attributed to the expanding use of cell therapies in treating various conditions such as cancer, autoimmune diseases, cardiovascular ailments, and other chronic illnesses.

The rising prevalence of long-term conditions has led to a surge in the adoption of cell therapies. According to the Centers for Disease Control and Prevention, 6 out of 10 adults in the U.S. have at least one chronic condition, with 4 in 10 adults affected by two or more. In cell therapy, damaged tissue is replaced with healthy counterparts or by stimulating tissue repair and regeneration. The segment's growth is further propelled by increased approvals for cell therapy and a growing body of positive clinical outcomes associated with regenerative cells.

By Application: In 2024, the Musculoskeletal Segment to Dominate the Regenerative Medicine Market

Based on application, the regenerative medicine market is segmented into cardiology, ophthalmology, oncology, neurology, immunology & inflammation, musculoskeletal, dermatology, and other applications. In 2024, the musculoskeletal segment is expected to account for the largest share of 31.9% of the regenerative medicine market. Conditions that affect the joints and certain connective tissues are known as musculoskeletal conditions. The high incidence of bone-related injuries and the rising prevalence of musculoskeletal disease are increasing the demand for regenerative medicine.

According to the Australian Institute of Health and Welfare, around 7.3 million people (29%) in Australia are estimated to be living with chronic musculoskeletal conditions. Additionally, the increasing preference for regenerative medicine over surgery for muscle strain injuries in athletes and partial tendon tears is further contributing to the significant market share of this segment.

By End User: In 2024, the Hospital & Clinics Segment to Dominate the Regenerative Medicine Market

Based on end user, the regenerative medicine market is segmented into hospitals & clinics and ambulatory surgical centers. In 2024, the hospitals & clinics segment is expected to account for the larger share of the regenerative medicine market. This segment’s large market share can be attributed to the rising number of patient visits to hospitals, the growing number of hospitals, and the availability of advanced technological resources within these healthcare facilities. Additionally, funding is often provided to hospitals & clinics to establish dedicated regenerative medicine facilities. For instance, in October 2022, California's stem cell agency granted $8 million to Cedars-Sinai (U.S.), a non-profit teaching hospital and multi-specialty academic health science center. This grant aims to establish an Alpha Stem Cell Clinic, enhancing patient access to stem cell therapy.

Geographical Analysis

In 2024, North America is expected to account for the largest share of the 41.8% of regenerative medicine market. North America’s significant market share can be attributed to the increasing prevalence of target diseases such as cancer and cardiovascular diseases, growing funding for the development of regenerative medicine, the presence of key market players in the region, and the rising number of clinical trials. According to the Alliance for Regenerative Medicine (U.S.), an international organization for regenerative medicine, North America witnessed a notable increase in the number of clinical trials, reaching 394 trials during the third quarter of 2023 from 339 trials in the fourth quarter of 2022. Similarly, the number of developers engaged in cell therapy manufacturing in North America increased from 272 to 435 during the same period. This surge in clinical trials and the involvement of key players in the development of regenerative medicine contribute to North America’s significant market share.

However, the market in Asia-Pacific is projected to register the highest CAGR of 25.0% during the forecast period. The growth of this regional market is attributed to the rising prevalence of target diseases, the growing adoption of stem cell technology, supportive government policies promoting the development of regenerative medicine, and increased funding and research and development (R&D) initiatives in this field. According to the Alliance for Regenerative Medicine (U.S.), investment in regenerative medicine in the Asia-Pacific region surged to $2.1 billion in the fourth quarter of 2023, up from $0.9 billion in the third quarter of the same year.

Regenerative Medicine Market: Key Companies

The report offers a competitive landscape based on an extensive assessment of the offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past three to four years. The key players operating in the regenerative medicine market are Novartis AG (Switzerland), Biogen Inc. (U.S.), Kite Pharma, Inc. (U.S.), Spark Therapeutics, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Sarepta Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (England), Vertex Pharmaceuticals Incorporated (U.S.), CSL Behring, LLC (U.S.), Janssen Global Services, LLC (U.S.), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Ferring Pharmaceuticals A/S (Sweden), Pfizer Inc. (U.S.), bluebird bio Inc. (U.S.), and Vericel Corporation (U.S.).

Regenerative Medicine Market Overview: Latest Developments from Key Industry Players

In May 2024, Bristol-Myers Squibb Company (U.S.) received approval from the U.S. FDA for Breyanzi, a CAR T-cell therapy used to treat relapsed or refractory mantle cell lymphoma (MCL) and refractory follicular lymphoma in adult patients.
In April 2024, AbbVie Inc. partnered with REGENXBIO Inc. (U.S.) to develop ABBV-RGX-314, a gene therapy for retinal diseases, specifically neovascular age-related macular degeneration and diabetic retinopathy.
In January 2024, Smith & Nephew plc (U.K.) acquired CartiHeal Ltd. (Israel), a company that develops Agili-C, an innovative sports medicine technology designed for cartilage regeneration in the knee.
In May 2023, Integra LifeSciences Holdings Corporation (U.S.) established a new Center of Innovation and Learning aimed at advancing regenerative technologies to meet critical clinical needs.

Regenerative Medicine Market Research Summary

Particulars	Details
Number of Pages	248
Format	PDF
Forecast Period	2024-2031
Base Year	2023
CAGR	21.5%
Estimated Market Size (Value)	$37.27 billion by 2031
Segments Covered	By Product Gene Therapy Cell Therapy Stem Cell Therapy Autologous Therapy Allogenic Therapy Platelet Rich Plasma Therapy Cell-based Immunotherapy Tissue Engineering Products By Application Cardiology Ophthalmology Oncology Neurology Immunology & Inflammation Musculoskeletal Dermatology Other Applications (Note: Other applications majorly include wound care, orthopedics, and sports injuries.) By End User Hospitals & Clinics Ambulatory Surgical Centers
Countries Covered	North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Netherlands, Sweden, Switzerland, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa
Key Companies	Novartis AG (Switzerland), Biogen Inc. (U.S.), Kite Pharma, Inc. (U.S.), Spark Therapeutics, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Sarepta Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (England), Vertex Pharmaceuticals Incorporated (U.S.), CSL Behring, LLC (U.S.), Janssen Global Services, LLC (U.S.), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Ferring Pharmaceuticals A/S (Sweden), Pfizer Inc. (U.S.), bluebird bio Inc. (U.S.), and Vericel Corporation (U.S.).

Key questions answered in the regenerative market report:

What is the focus of the regenerative medicine market study?

The regenerative medicine market report analyzes various segments of regenerative medicine, such as product, application, and end user, at the regional and country levels. It also provides insights on factors impacting market growth, regulatory analysis, investment and funding scenarios, pipeline analysis, and Porter’s five forces analysis.

What is the revenue generated from the sales of regenerative medicine across the globe?

The regenerative medicine market was valued at $7.91 billion in 2023. This market is expected to reach $37.27 billion by 2031 from an estimated $9.52 billion in 2024, at a CAGR of 21.5% during the forecast period from 2024 to 2031.

Which product segment is estimated to hold the major share of the market in 2024?

Among the products covered in this report, in 2024, the cell therapy segment is expected to account for the largest share of 51.2% of the regenerative medicine market. Stem cell therapy is a minimally invasive procedure, reducing the need for extensive surgeries and lengthy recovery periods. Since it utilizes the patient's body cells, it minimizes the risk of side effects and provides personalized treatment, making it a preferred option over other therapies.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the regenerative medicine market?

The growth of this market is driven by factors such as the growing drug approvals for regenerative medicine, advancements in regenerative medicine, the rising incidences of target diseases, the expanding usage of regenerative medicine in newer therapies, and increasing funding for research & development of regenerative medicine. Furthermore, the growing demand for personalized medicine, the soaring demand for organ transplants, and the rising number of drugs in the pipeline are expected to create market growth opportunities.

Who are the major players operating in the regenerative medicine market?

The key players operating in the regenerative medicine market are Novartis AG (Switzerland), Biogen Inc. (U.S.), Kite Pharma, Inc. (U.S.), Spark Therapeutics, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Sarepta Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (England), Vertex Pharmaceuticals Incorporated (U.S.), CSL Behring, LLC (U.S.), Janssen Global Services, LLC (U.S.), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Ferring Pharmaceuticals A/S (Sweden), Pfizer Inc. (U.S.), bluebird bio Inc. (U.S.), and Vericel Corporation (U.S.).

Which regions/countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

Asia-Pacific is slated to register the highest growth rate of 25.0% during the forecast period. This regional market's growth is attributed to the rising prevalence of target diseases, the growing adoption of stem cell technology, supportive government policies promoting the development of regenerative medicine, and increased funding and research and development (R&D) initiatives in this field.

Enquire

Check Discount

Related Tag: Regenerative Medicine Market Regenerative Therapy Regenerative Treatments CAR T Cell Stem Cell Regenerative Biology Cell Therapy

Medical Technologies

Healthcare

1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Data Collection and Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews With Key Opinion Leaders from the Industry
2.3. Market Sizing & Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Approvals for New Regenerative Medicines
4.2.1.2. Increasing Funding for Regenerative Medicine Development
4.2.1.3. Increasing Applications of Regenerative Medicine in Newer Therapy Areas
4.2.2. Restraints
4.2.2.1. Ethical Issues Related to Stem Cells
4.2.3. Opportunities
4.2.3.1. Rising Demand for Personalized Medicines
4.2.4. Challenges
4.2.4.1. Complexities in the Manufacture of Regenerative Medicines
4.2.5. Factor Analysis
4.3. Trends
4.3.1. Utilization of 3D Bioprinting in Regenerative Medicine
4.3.2. Integration of AI Tools in Regenerative Medicine Development
4.3.3. Induced Pluripotent Stem Cells
4.4. Regulatory Analysis
4.4.1. North America
4.4.1.1. U.S.
4.4.1.2. Canada
4.4.2. Asia-Pacific
4.4.2.1. Japan
4.4.2.2. China
4.4.2.3. India
4.4.3. Europe
4.4.4. Middle East & Africa
4.4.5. PRP Qualification Criteria
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
4.6. Investment and Funding Scenario
4.7. Pipeline Analysis

5. Regenerative Medicine Market Assessment—by Product
5.1. Overview
5.2. Cell Therapy
5.2.1. Cell-based Immunotherapy
5.2.2. Stem Cell Therapy
5.2.2.1. Allogenic Therapy
5.2.2.2. Autologous Therapy
5.2.3. Platelet-rich Plasma Therapy
5.3. Gene Therapy
5.4. Tissue Engineering Products

6. Regenerative Medicine Market Assessment—by Application
6.1. Overview
6.2. Musculoskeletal
6.3. Oncology
6.4. Ophthalmology
6.5. Immunology & Inflammation
6.6. Neurology
6.7. Dermatology
6.8. Cardiology
6.9. Other Applications

7. Regenerative Medicine Market Assessment—by End User
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Ambulatory Surgical Centers

8. Regenerative Medicine Market Assessment—by Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. U.K.
8.3.3. France
8.3.4. Switzerland
8.3.5. Italy
8.3.6. Spain
8.3.7. Netherlands
8.3.8. Sweden
8.3.9. Rest of Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. Australia
8.4.4. India
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America
8.6. Middle East & Africa

9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis (2023)
9.5.1. Novartis AG (Switzerland)
9.5.2. Kite Pharma, Inc. (U.S.)
9.5.3. Biogen, Inc. (U.S.)
9.5.4. Bristol-Myers Squibb Company (U.S.)
9.5.5. Janssen Global Services, LLC (U.S.)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis*)
10.1. Novartis AG
10.2. Kite Pharma, Inc. (A Subsidiary of Gilead Sciences, Inc.)
10.3. Janssen Global Services, LLC (A Subsidiary of Johnson & Johnson)
10.4. Bristol-Myers Squibb Company
10.5. Biogen Inc.
10.6. Smith & Nephew Plc
10.7. Amgen Inc.
10.8. Vericel Corporation
10.9. Integra Lifesciences Holdings Corporation
10.10. Pfizer Inc.
10.11. AbbVie Inc.
10.12. Sarepta Therapeutics, Inc.
10.13. Spark Therapeutics, Inc. (A Subsidiary of F. Hoffmann-La Roche Ag)
10.14. CORESTEMCHEMON, Inc.
10.15. CSL Behring, LLC (A Subsidiary of CSL Limited)
10.16. Takeda Pharmaceutical Company Limited
10.17. Ferring Pharmaceuticals
10.18. Medtronic plc
10.19. Bluebird Bio, Inc.
10.20. Vertex Pharmaceuticals Incorporated
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

11. Appendix
11.1. Available Customization
11.2. Related Reports

List of Tables
Table 1   U.S. FDA-Approved Cell & Gene Therapy Products (As of August 2024)
Table 2   Estimated Number of New Cancer Cases, by Region, 2022-2030 (Thousand)
Table 3   Comparison of Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation
Table 4   Risk Classification of Regenerative Medicines, by Type and Class
Table 5   Authorities/Organizations Funding and Investing In Regenerative Medicine-related Research & Development
Table 6   Regenerative Medicine Market: Pipeline Analysis
Table 7   Global Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 8   Estimated Number of New Leukemia Cases, by Region, 2022–2030 (Thousands)
Table 9   Global Regenerative Medicine Market for Cell Therapy, by Type, 2022–2031 (USD Million)
Table 10   Global Regenerative Medicine Market for Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 11   Companies Offering Cell-Based Immunotherapy Solutions
Table 12   Global Regenerative Medicine Market for Cell-Based Immunotherapy, by Country/Region, 2022–2031 (USD Million)
Table 13   Companies Offering Stem Cell Therapy Solutions
Table 14   Characteristics Features of Stem Cell Therapy for Regenerative Medicine
Table 15   Global Stem Cell Therapy Market, by Type, 2022–2031 (USD Million)
Table 16   Global Regenerative Medicine Market for Stem Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 17   Companies Offering Allogenic Therapy Solutions
Table 18   Global Regenerative Medicine Market for Allogenic Therapy, by Country/Region, 2022–2031 (USD Million)
Table 19   Companies Offering Autologous Cell Therapy
Table 20   Global Regenerative Medicine Market for Autologous Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 21   Companies Offering Platelet-Rich Plasma (PRP) Therapy
Table 22   Global Regenerative Medicine for Platelet-Rich Plasma (PRP) Therapy, by Country/Region, 2022–2031 (USD Million)
Table 23   Companies Offering Gene Therapy Products
Table 24   Global Regenerative Medicine Market for Gene Therapy, by Country/Region, 2022–2031 (USD Million)
Table 25   Companies Offering Tissue Engineering Products
Table 26   Global Regenerative Medicine Market for Tissue Engineering Products, by Country/Region, 2022–2031 (USD Million)
Table 27   Global Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 28   Global Regenerative Medicine Market for Musculoskeletal Disorders, by Country/Region, 2022–2031 (USD Million)
Table 29   Global Regenerative Medicine Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 30   Global Regenerative Medicine Market for Ophthalmology, by Country/Region, 2022–2031 (USD Million)
Table 31   Global Regenerative Medicine Market for Immunology & Inflammation, by Country/Region, 2022–2031 (USD Million)
Table 32   Global Regenerative Medicine Market for Neurology, by Country/Region, 2022–2031 (USD Million)
Table 33   Global Regenerative Medicine Market for Dermatology, by Country/Region, 2022–2031 (USD Million)
Table 34   Global Regenerative Medicine Market for Cardiology, by Country/Region, 2022–2031 (USD Million)
Table 35   Global Regenerative Medicine Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 36   Global Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 37   Global Regenerative Medicine Market for Hospitals & Clinics, by Country/Region, 2022-2031 (USD Million)
Table 38   Global Regenerative Medicine Market for Ambulatory Surgical Centers, by Country/Region, 2022-2031 (USD Million)
Table 39   Global Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 40   North America: Regenerative Medicine Market, by Country, 2022–2031 (USD Million)
Table 41   North America: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 42   North America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 43   North America: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 44   North America: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 45   North America: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 46   U.S.: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 47   U.S.: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 48   U.S.: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 49   U.S.: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 50   U.S.: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 51   Canada: Approved Regenerative Medicine, 2021-2024
Table 52   Canada: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 53   Canada: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 54   Canada: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 55   Canada: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 56   Canada: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 57   Europe: Regenerative Medicine Sector Data, Q2 2024 Vs. Q1 2023
Table 58   Europe: Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 59   Europe: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 60   Europe: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 61   Europe: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 62   Europe: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 63   Europe: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 64   Germany: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 65   Germany: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 66   Germany: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 67   Germany: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 68   Germany: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 69   U.K.: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 70   U.K.: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 71   U.K.: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 72   U.K.: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 73   U.K.: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 74 France: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 75 France: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 76 France: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 77 France: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 78 France: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 79   Switzerland: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 80   Switzerland: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 81   Switzerland: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 82   Switzerland: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 83   Switzerland: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 84   Italy: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 85   Italy: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 86   Italy: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 87   Italy: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 88   Italy: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 89   Spain: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 90   Spain: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 91   Spain: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 92   Spain: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 93   Spain: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 94   Netherlands: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 95   Netherlands: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 96   Netherlands: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 97   Netherlands: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 98   Netherlands: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 99   Sweden: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 100   Sweden: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 101   Sweden: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 102   Sweden: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 103   Sweden: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 104   Rest of Europe: Estimated Number of New Cancer Cases, by Country, 2022 Vs. 2030
Table 105   Rest of Europe: Recent Developments In The Regenerative Medicine Market
Table 106   Rest of Europe: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 107   Rest of Europe: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 108   Rest of Europe: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 109   Rest of Europe: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 110   Rest of Europe: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 111   Asia-Pacific: Regenerative Medicine Sector Data, Q2 2024 Vs. Q1 2023
Table 112   Asia-Pacific: Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 113   Asia-Pacific: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 114   Asia-Pacific: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 115   Asia-Pacific: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 116   Asia-Pacific: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 117   Asia-Pacific: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 118   Japan: Approved Regenerative Medicine
Table 119   Japan: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 120   Japan: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 121   Japan: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 122   Japan: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 123   Japan: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 124   China: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 125   China: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 126   China: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 127   China: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 128   China: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 129   Australia: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 130   Australia: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 131   Australia: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 132   Australia: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 133   Australia: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 134   India: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 135   India: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 136   India: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 137   India: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 138   India: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 139   South Korea: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 140   South Korea: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 141   South Korea: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 142   South Korea: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 143   South Korea: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 144   Rest of Asia-Pacific: Recent Developments in Regenerative Medicine Market, by Country
Table 145   Rest of Asia-Pacific: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 146   Rest of Asia-Pacific: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 147   Rest of Asia-Pacific: Stem Cell Therapy Market, by Type, 2022–2031 (USD Million)
Table 148   Rest of Asia-Pacific: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 149   Rest of Asia-Pacific: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 150   Latin America: Regenerative Medicine Market, by Country/Region, 2022–2031 (USD Million)
Table 151   Latin America: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 152   Latin America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 153   Latin America: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 154   Latin America: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
Table 155   Latin America: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 156   Brazil: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 157   Brazil: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 158   Brazil: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 159   Brazil: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 160   Brazil: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 161   Mexico: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 162   Mexico: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 163   Mexico: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 164   Mexico: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 165   Mexico: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 166   Rest of Latin America: Regenerative Medicine Market, by Product, 2022–2031 (USD Million)
Table 167   Rest of Latin America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 168   Rest of Latin America: Stem Cell Therapy Market, by Type, 2022–2031 (USD Million)
Table 169   Rest of Latin America: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 170   Rest of Latin America: Regenerative Medicine Market, by End User, 2022–2031 (USD Million)
Table 171   Middle East & Africa: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
Table 172   Middle East & Africa: Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 173   Middle East & Africa: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
Table 174   Middle East & Africa: Regenerative Medicine Market, by Application, 2022–2031 (USD Million)
Table 175   Middle East & Africa: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
Table 176   Recent Developments, by Company, 2021–2024

List of Figures
Figure 1   Research Process
Figure 2   Secondary Sources Referenced for this Study.
Figure 3   Primary Research Techniques
Figure 4   Key Executives Interviewed
Figure 5   Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6   Market Sizing And Growth Forecast Approach
Figure 7   Global Regenerative Medicine Market, by Product, 2024 VS. 2031 (USD Million)
Figure 8   Global Regenerative Medicine Market, by Application, 2024 VS. 2031 (USD Million)
Figure 9   Global Regenerative Medicine Market, by End User, 2024 VS. 2031 (USD Million)
Figure 10   Global Regenerative Medicine Market, by Geography
Figure 11   Impact Analysis of Market Dynamics
Figure 12   NIH Funding for Regenerative Medicine, 2019-2025 (USD Million)
Figure 13   Japan: Regenerative Medicines Regulatory Pathway
Figure 14   India: Approval Pathway for Regenerative Medicines
Figure 15   Saudi Arabia: Drug Licensing - Marketing Authorization Process
Figure 16   Porter’s Five Forces Analysis
Figure 17   Investments In Regenerative Medicine, 2017-2023 (USD Billion)
Figure 18   Global Regenerative Medicine Market, by Product, 2024 Vs. 2031 (USD Million)
Figure 19   Cell-based Immunotherapy Workflow
Figure 20   Global Regenerative Medicine Market, by Application, 2024 VS. 2031 (USD Million)
Figure 21   Global Regenerative Medicine Market, by End User, 2024 VS. 2031 (USD Million)
Figure 22   Regenerative Medicine Market, by Geography, 2024 VS. 2031 (USD Million)
Figure 23   North America: Regenerative Medicine Market Snapshot
Figure 24   Europe: Regenerative Medicine Market Snapshot
Figure 25   Asia-Pacific: Regenerative Medicine Market Snapshot
Figure 26   Latin America: Regenerative Medicine Market Snapshot
Figure 27   Key Growth Strategies Adopted by Leading Players, 2021–2024
Figure 28   Regenerative Medicine Market: Competitive Benchmarking, by Product
Figure 29   Regenerative Medicine Market: Competitive Benchmarking, by Region
Figure 30   Competitive Dashboard: Regenerative Medicine Market
Figure 31   Global Regenerative Medicine Market Share Analysis, by Key Players (2023)
Figure 32   Novartis AG: Financial Snapshot (2023)
Figure 33   Gilead Sciences, Inc.: Financial Overview (2023)
Figure 34   Johnson & Johnson.: Financial Overview (2023)
Figure 35   Bristol-Myers Squibb Company: Financial Overview (2023)
Figure 36   Biogen Inc.: Financial Snapshot (2023)
Figure 37   Smith & Nephew Plc: Financial Overview (2023)
Figure 38   Amgen Inc.: Financial Overview (2023)
Figure 39   Vericel CORPORATION.: Financial Overview (2023)
Figure 40   Integra Lifesciences Holdings Corporation.: Financial Snapshot (2023)
Figure 41   Pfizer Inc.: Financial Snapshot (2023)
Figure 42   AbbVie Inc: Financial Overview (2023)
Figure 43   Sarepta Therapeutics, Inc.: Financial Snapshot (2023)
Figure 44 F. Hoffmann-La Roche AG: Financial Snapshot (2023)
Figure 45   CORESTEMCHEMON, Inc.: Financial Overview (2022)
Figure 46   CSL LIMITED: Financial Overview (2024)
Figure 47 Takeda Pharmaceutical Company Limited: Financial Overview (2023)
Figure 48 Ferring Pharmaceuticals: Financial Overview (2023)
Figure 49   Medtronic plc: Financial Overview (2024)
Figure 50   bluebird bio, Inc.: Financial Overview (2023)
Figure 51   Vertex Pharmaceuticals Incorporated: Financial Overview (2023)